Impact Biomedicines

What Impact Biomedicines does

Impact Biomedicines is a San Diego-based biopharmaceutical company founded in 2016 that develops and commercializes treatments for rare diseases, with a primary focus on myelofibrosis. Its lead product, Inrebic (fedratinib), is an FDA-approved JAK2 inhibitor indicated for the treatment of myelofibrosis, a rare blood cancer. The company originated as an independent biotech funded by approximately $112 million in 2017 (notably a $90 million round led by Oberland Capital and a $22 million Series 2 led by Medicxi) and was subsequently acquired by Bristol Myers Squibb, operating today as a wholly-owned BMS subsidiary. Scientific leadership is anchored by co-founder Catriona Jamieson (currently Interim Chief Medical Officer) and Charles McDermott (President and Chief Business Officer).

The company's business model is asset-centric and licensing-oriented rather than built on direct commercial infrastructure. Impact monetizes Inrebic through regional licensing partnerships — exemplified by the February 2026 exclusive license to Recordati S.p.A. for the Japanese market, which generated an $11 million upfront payment. The model leverages Bristol Myers Squibb's global commercial reach for core markets and uses specialty regional partners to extend geographic access for the orphan-indication asset.

Impact Biomedicines serves a narrow patient population of myelofibrosis and other rare-disease patients, primarily in geographies where its parent or licensing partners have established commercial or distribution capability. The company's strategic positioning is as a focused hematology/rare-disease vehicle within BMS's broader oncology, hematology, neuroscience, immunology, and cardiovascular portfolio, concentrating spend on Inrebic lifecycle management and potential label or geographic expansion rather than broad pipeline diversification at the subsidiary level.

Name

Impact Biomedicines

Legal name

Impact Biomedicines

Website

https://impactbiomedicines.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Impact Biomedicines is a Bristol Myers Squibb subsidiary that develops and licenses Inrebic (fedratinib), an FDA-approved JAK2 inhibitor for myelofibrosis, monetizing the rare-disease asset through regional licensing partnerships such as its Japan deal with Recordati.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Rare disease therapeutics
• JAK2 inhibitor drugs
• Myelofibrosis treatment
• Specialty pharmaceuticals
• Drug licensing

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Licensing - Inrebic Japan: Impact Biomedicines, a Bristol Myers Squibb subsidiary, generates revenue through licensing agreements. Recordati obtained an exclusive license for Inrebic in Japan, paying $11 million upfront to Impact Biomedicines/Bristol Myers Squibb.

Core offering

Impact Biomedicines develops and holds rights to Inrebic (fedratinib), a JAK2 inhibitor for the treatment of myelofibrosis. The company commercializes the drug primarily through regional licensing partnerships, having granted Recordati an exclusive license for the Japanese market for an $11 million upfront payment, while operating under the Bristol Myers Squibb umbrella for broader development and distribution capabilities.

Product overview

Impact Biomedicines is a subsidiary of Bristol Myers Squibb focused on rare diseases and specialty pharmaceuticals. The company's primary product is Inrebic (fedratinib), a JAK2 inhibitor for myelofibrosis, which has been licensed to Recordati for distribution in Japan. Impact Biomedicines operates within BMS's broader portfolio spanning oncology, hematology, neuroscience, immunology, and cardiovascular therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Inrebic (fedratinib)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Recordati S.p.A.coreOEM/ Whitelabel/ Licensing Partner · 17 February 2026Recordati obtained an exclusive license for Inrebic (fedratinib) in Japan from Bristol Myers Squibb subsidiary Impact Biomedicines. Recordati paid $11 million upfront for this regional licensing agreement. This partnership enables Recordati to commercialize Inrebic in the Japanese market, expanding access to this rare disease treatment for myelofibrosis patients in Japan. The deal was announced as part of Recordati's broader business development strategy to expand its rare diseases portfolio.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Incyte Corporation: Incyte markets Jakafi (ruxolitinib), the leading JAK1/2 inhibitor and first-line standard of care for myelofibrosis. It is the most direct therapeutic competitor to Impact Biomedicines' Inrebic (fedratinib) in the same indication.
• CTI BioPharma: CTI BioPharma developed Vonjo (pacritinib), an FDA-approved JAK2 inhibitor for myelofibrosis patients with severe thrombocytopenia, directly competing with Inrebic in the same disease segment.

Emerging players

• Sierra Oncology (acquired by GSK): Sierra Oncology developed momelotinib, another JAK1/2/ACVR1 inhibitor for myelofibrosis, representing another direct competitor in the JAK-inhibitor space targeting the same patient population as Impact Biomedicines.
• Geron Corporation: Geron is developing imetelstat for hematologic malignancies including myelofibrosis, representing an emerging non-JAK mechanism competitor that could disrupt the standard-of-care landscape for Impact Biomedicines' Inrebic.

Broad incumbents

• Bristol Myers Squibb: Parent company of Impact Biomedicines and a global biopharmaceutical leader with broad hematology/oncology franchise. BMS operates across multiple therapeutic areas, with Inrebic folded into its larger specialty oncology portfolio.
• Pfizer: Pfizer markets Xeljanz (tofacitinib), a JAK inhibitor whose class-wide safety findings (cardiovascular, malignancy) shaped the regulatory environment for all JAK agents including Inrebic. Pfizer also has broad hematology/oncology capabilities.
• AbbVie: AbbVie markets Imbruvica (ibrutinib) and Venclexta (venetoclax), establishing it as a major hematology franchise operator with comparable specialty/hematology commercial infrastructure relevant to Impact Biomedicines' positioning.
• GSK: GSK acquired Sierra Oncology and its myelofibrosis drug momelotinib, positioning it as a broad incumbent with both JAK and adjacent hematology assets overlapping Impact Biomedicines' therapeutic space.
• Novartis: Novartis operates a major global hematology franchise (e.g., Jakavi/ruxolitinib ex-US rights) and is a relevant broad incumbent peer in the JAK/myelofibrosis commercial landscape.

Others

• Recordati S.p.A. Recordati is Impact Biomedicines' licensing partner for Inrebic in Japan and a broader European specialty pharma with rare disease focus. Comparable as a rare-disease commercial partner/specialty pharma operator.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ImpactBioMed

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impact Biomedicines